×
About 323 results

ALLMedicine™ Hyperglucagonemia Center

Research & Reviews  107 results

GC-globulin/vitamin D-binding protein is Required for Pancreatic α Cell Adaptation to M...
https://doi.org/10.2337/db22-0326
Diabetes Viloria K, Nasteska D et. al.

Nov 30th, 2022 - GC-globulin (GC), or vitamin D-binding protein, is a multifunctional protein involved in transport of circulating vitamin 25(OH)D and fatty acids, as well as actin-scavenging. In the pancreatic islets, the gene encoding GC, GC, is highly-localized...

G-Protein-Coupled Lactate Receptor GPR81 Control of VMNvl Glucoregulatory Neurotransmit...
https://doi.org/10.1152/ajpregu.00100.2022
American Journal of Physiology. Regulatory, Integrative A... Roy SC, Napit PR et. al.

Nov 22nd, 2022 - Astrocytes store glycogen as energy and promote neuro-metabolic stability through supply of oxidizable L-lactate. Whether lactate regulates ventromedial hypothalamic nucleus (VMN) glucostatic function as a metabolic volume transmitter is unknown. ...

Glucagon Response to Prandial Insulin Administration in Persons With Type 1 Diabetes
https://clinicaltrials.gov/ct2/show/NCT04079881

Oct 7th, 2022 - Glucagon regulation and response in persons with T1D at the basal state and in response to various stimuli remains unclear. Dr. Philip Cryer has previously reported that, in T1D young adults with a course of the disease of 16+9 years, the absence ...

Glucagon receptor antagonist volagidemab in type 1 diabetes: a 12-week, randomized, dou...
https://doi.org/10.1038/s41591-022-02011-x
Nature Medicine; Pettus J, Boeder SC et. al.

Oct 4th, 2022 - Hyperglucagonemia contributes to hyperglycemia in patients with type 1 diabetes (T1D); however, novel therapeutics that block glucagon action could improve glycemic control. This phase 2 study evaluated the safety and efficacy of volagidemab, an a...

Alpha Cell Thioredoxin-interacting Protein Deletion Improves Diabetes-associated Hyperg...
https://doi.org/10.1210/endocr/bqac133
Endocrinology Lu B, Chen J et. al.

Aug 13th, 2022 - Thioredoxin-interacting protein (TXNIP) has emerged as a key factor in pancreatic beta cell biology, and its upregulation by glucose and diabetes contributes to the impairment in functional beta cell mass and glucose homeostasis. In addition, beta...

see more →

Clinicaltrials.gov  18 results

Glucagon Response to Prandial Insulin Administration in Persons With Type 1 Diabetes
https://clinicaltrials.gov/ct2/show/NCT04079881

Oct 7th, 2022 - Glucagon regulation and response in persons with T1D at the basal state and in response to various stimuli remains unclear. Dr. Philip Cryer has previously reported that, in T1D young adults with a course of the disease of 16+9 years, the absence ...

Development and Evaluation of a Glucagon Sensitivity Test in Individuals With and Without Hepatic Steatosis
https://clinicaltrials.gov/ct2/show/NCT04907721

May 18th, 2022 - Amino acids administered orally or intravenously stimulate glucagon secretion from the pancreas and in turn, glucagon is a powerful stimulus for hepatic amino acid turnover through transcriptional (long-term) and non- transcriptional (acute) mecha...

Lowering Impaired Fasting Glucose Levels With Exercise
https://clinicaltrials.gov/ct2/show/NCT03019510

Oct 21st, 2021 - In individuals with type 2 diabetes (T2D), chronically elevated glucose and insulin levels result in numerous health complications. Maintaining tight glucose control is difficult for individuals with T2D, particularly in the postprandial period an...

Glucagon Resistance in Patients With NAFLD
https://clinicaltrials.gov/ct2/show/NCT04042142

Sep 9th, 2021 - The investigators propose that the sensitivity to glucagon in hepatic lipid metabolism is impaired in subjects with non-alcoholic fatty liver disease (NAFLD) and steatohepatitis (NASH). Moreover, they propose a dys-coordinated, reduced glucagon se...

The Effect of Lifestyle-induced Hepatic Steatosis on Glucagon-stimulated Amino Acid Turnover
https://clinicaltrials.gov/ct2/show/NCT04859322

Apr 30th, 2021 - Many patients with type 2 diabetes exhibit elevated plasma concentrations of the glucose-mobilising pancreatic hormone glucagon; i.e. hyperglucagonaemia. This contributes to the hyperglycaemic state of the patients and is considered an important c...

see more →

News  4 results

Multiple Metabolic Abnormalities Seen in Lupus
https://www.medpagetoday.com/rheumatology/lupus/64321

Apr 4th, 2017 - Lupus patients had a bi-hormone metabolic abnormality characterized by increased insulin resistance and glucagon levels, despite normal glucose tolerance, according to a Brazilian study. When compared with a control group, patients with systemic l...

Glucagon Receptor Blockers Eyed for Type 2
https://www.mdedge.com/endocrinology/article/53198/diabetes/glucagon-receptor-blockers-eyed-type-2
Miriam E. Tucker

Oct 1st, 2011 - LISBON – New data on two investigational glucagon receptor antagonists suggest that this novel class of drugs has potential to be an effective treatment for type 2 diabetes, but only if safety can be established, according to two presentations at.

Investigational Glucagon Antagonists Show Promise for Diabetes
https://www.mdedge.com/internalmedicine/article/40654/endocrinology/investigational-glucagon-antagonists-show-promise
Miriam E. Tucker

Sep 16th, 2011 - LISBON – New data on two investigational glucagon receptor antagonists suggest that this novel class of drugs has potential to be an effective treatment for type 2 diabetes, but only if safety can be established, according to two presentations at.

Euglycemic Diabetic Ketoacidosis: A Potential Complication of Treatment With Sodium–Glucose Cotransporter 2 Inhibition
https://www.medscape.com/viewarticle/850125

Abstract and Introduction Abstract Objective Sodium–glucose cotransporter 2 (SGLT-2) inhibitors are the most recently approved antihyperglycemic medications. We sought to describe their association with euglycemic diabetic ketoacidosis (euDKA) in ...

see more →